Drug Profile


Alternative Names: BOF A2; Last-F

Latest Information Update: 20 Oct 2006

Price : $50

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Gastrointestinal cancer; Lung cancer; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 15 Mar 2001 A phase I study has been added to the Cancer adverse events and pharmacokinetics sections
  • 28 Feb 2000 Preregistration for Non-small cell lung cancer in Japan (PO)
  • 28 Feb 2000 Preregistration for Lung cancer in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top